Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.49 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | CHI3L1 | P36222 | 1/20 | 0.43 |
| ▸ | CHIT1 | Q13231 | 1/20 | 0.43 |
| ▸ | CHI3L2 | Q15782 | 1/20 | 0.43 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27837194 | 0.82 | TAAR1 (0.65) | TAAR1GRIN2BHTR2ACHIT1CHIA | |
| SCHEMBL25833470 | 0.82 | TAAR1 (0.65) | TAAR1GRIN2BHTR2ACHI3L1CHIT1 | |
| SCHEMBL1967143 | 0.80 | GRIN2B (0.63) | TAAR1GRIN2BHTR2ACHIASLC18A3 | |
| SCHEMBL1965728 | 0.80 | AOC3 (0.63) | TAAR1HRH3 | |
| SCHEMBL1967611 | 0.79 | CHIA (0.54) | TAAR1GRIN2BHRH3HTR2ACHI3L1 | |
| SCHEMBL3055268 | 0.78 | TAAR1 (0.63) | TAAR1HRH3 | |
| SCHEMBL1970890 | 0.78 | CHIT1 (0.47) | GRIN2BHRH3HTR2ACHI3L1CHIT1 | |
| SCHEMBL1967604 | 0.75 | SIGMAR1 (0.60) | GRIN2BHRH3HTR2ASLC6A2SLC6A4 | |
| SCHEMBL18774063 | 0.75 | TAAR1 (0.55) | TAAR1HRH3 | |
| SCHEMBL19444655 | 0.75 | TAAR1 (0.59) | TAAR1HRH3CHI3L1CHIT1CHI3L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-01 | — | — | US | disclosed |
| EP-2334643-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | Actelion Pharmaceuticals Ltd. (CH) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010044054-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | HCRTR2, HCRTR1, HRH3 | TAAR1 48/4885GRIN2B 223/4885HRH3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.